Indeed, targeting PI3Kγ is even more effective than cytarabine in PIK3R5-elevated AML cells without clear side effects, and eganelisib synergizes with cytarabine to inhibit tumor growth in vivo. The gene discussed is PIK3R5; the disease is neoplasm.